A comprehensive summary of the latest clinical trial data, meta-analyses, safety profiles, and regulatory developments in psilocybin-assisted therapy for treatment-resistant depression.
Psilocybin-assisted therapy has emerged as a breakthrough treatment for treatment-resistant depression (TRD), with multiple Phase 2 and Phase 3 trials demonstrating significant efficacy. The COMPASS Pathways COMP360 trial is the largest and most rigorous psilocybin study to date, with results published in the New England Journal of Medicine.
A single 25 mg dose of psilocybin, combined with psychological support, produces rapid and significant reductions in depressive symptoms that persist for up to 12 weeks — in patients who have failed 2-4 prior antidepressant treatments.
"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression"
Published in the New England Journal of Medicine (November 2, 2022). Phase 2b, double-blind, randomised controlled trial — the largest psilocybin treatment trial ever conducted.
This represents a severely treatment-resistant population with chronic, persistent depression:
| Dose | Baseline | Week 3 | Change | vs. 1 mg | p-value |
|---|---|---|---|---|---|
| 25 mg | 31.9 | 19.9 | -12.0 | -6.6 | p<0.001 |
| 10 mg | 33.0 | 25.1 | -7.9 | -2.5 | p=0.18 |
| 1 mg (control) | 32.7 | 27.2 | -5.4 | — | — |
The 25 mg dose showed highly statistically significant improvement vs. placebo (p<0.001), producing a 38% improvement in depression scores within 3 weeks.
The trial emphasised that psilocybin works best with structured psychological support, not as a standalone drug:
This multi-session, therapist-supported model is critical to outcomes. Psychotherapist competence is essential — psilocybin alone doesn't drive results.
COMPASS Pathways announced successful completion of two Phase 3 trials in February 2026. Both studies met their primary endpoints, with patients receiving COMP360 showing greater depression improvement than control groups.
"Taken together, the data probably meets the bar for approval. It doesn't shout out to you that this is miraculous."— Jerry Rosenbaum, Director, Center for Neuroscience of Psychedelics, Massachusetts General Hospital
Across 9 randomised controlled trials with 596 total participants:
Confirmed psilocybin demonstrates efficacy compared to placebo and non-psychoactive comparators. Effect magnitude supports potential utility in treatment-resistant cases. Long-term follow-up data beyond 3 months remains limited.
Important nuance: Current studies mostly compare psilocybin vs. placebo (passive control). Future trials using active controls (FDA-approved antidepressants) will likely show smaller effect size differences. This is expected and normal. The critical unanswered question remains: how long does the incremental effect last beyond 3 months?
| Dose | Efficacy | Significance |
|---|---|---|
| 25 mg | Optimal efficacy | Statistically significant vs. placebo |
| 10 mg | Subtherapeutic | Did not reach statistical significance |
| 1 mg | Control dose | Minimal effect |
Psilocybin appears to have a dose-response relationship. Higher doses (25 mg) are needed for reliable therapeutic effect in treatment-resistant populations.
Over 52 weeks, a single administration of 25 mg psilocybin suggested longer maintenance of antidepressant effect than both 1 mg and 10 mg doses.
Mount Sinai Expansion (2025): The Psychedelic Research Center expansion includes advanced imaging capabilities, molecular epigenetic studies, and research examining brain changes during therapy.
The STAR*D trial (historical gold standard) demonstrates why new treatments are urgently needed:
Approximately 40-50% of depressed patients fail to achieve remission with standard antidepressants.
| Treatment | Condition | Response Rate | Remission Rate | Protocol |
|---|---|---|---|---|
| Psilocybin (25 mg) | TRD | ~54% | ~29% | Single dose |
| MDMA-assisted | PTSD | 67-71% | — | 8-session protocol |
| Ketamine (IV) | TRD | 50-60% | 30-40% | Multiple sessions |
| Antidepressants | MDD | 30-40% | 20-30% | 4-6 weeks onset |
77% of participants (179 of 233) experienced adverse events — notably high, but most were mild-to-moderate and transient.
Suicidal ideation occurred at comparable rates across all dose groups, suggesting baseline depression severity (rather than psilocybin) drives suicidal risk. No treatment-limiting cardiac, hepatic, or haematologic adverse events were reported.
Drug Interactions: Serotonin syndrome risk with SSRIs — avoid concurrent use. Hypertensive crisis possible if antidepressants not discontinued. Psychological crisis requires trained psychiatric support on-site.
A February 2026 peer-reviewed analysis in the Australian & New Zealand Journal of Psychiatry identifies critical structural gaps in Australia's implementation of regulated psilocybin-assisted therapy:
The study recommends national training accreditation, evidence-based patient stratification models, and structural support to scale psychedelic-assisted therapy safely. Standardized clinician training is identified as essential infrastructure for responsible expansion of this treatment in Australia.
| Metric | Value | Clinical Significance |
|---|---|---|
| Effect Size (Meta-analysis) | SMD = -0.78 | Large, clinically significant |
| Response Rate (25 mg) | 54% | About 1 in 2 patients show ≥50% improvement |
| Remission Rate (25 mg) | 29% | About 1 in 3-4 patients achieve normal mood |
| Sustained Response (12 weeks) | 25% | About 1 in 4 maintain benefit |
| Adverse Event Rate | 77% | Mostly mild, transient (headache, nausea) |
| Time to Effect | 3 weeks | Much faster than SSRIs (4-6 weeks) |
| Treatment Duration | Single dose | One 6-8 hour session vs. months of medication |
| Trial Participants (Phase 2b) | 233 | Largest trial of its kind |
A landmark study conducted at St. Vincent's Hospital Melbourne examined psilocybin-assisted psychotherapy for depression, anxiety, and existential distress in adults with life-threatening illnesses — published in General Hospital Psychiatry (September–October 2025).
| Characteristic | Details |
|---|---|
| Participants | 35 adults (mean age 56, 54% female) with life-threatening illness and depression/anxiety |
| Arms | 25 mg psilocybin (n=17) vs. 100 mg niacin placebo (n=18); open-label extension for all |
| Follow-up | 26 weeks post open-label dose |
| Setting | Tertiary hospital palliative care department |
Sustained Benefits at 26 Weeks: Improvements in depression and anxiety persisted over 6+ months, suggesting durable effects in this population.
Beyond depression and anxiety, psilocybin produced significant improvements in existential distress:
This trial demonstrates that psilocybin-assisted psychotherapy addresses a critical unmet need in palliative care: existential suffering beyond conventional psychiatric symptomatology. Current antidepressants and anxiolytics show limited efficacy for death anxiety and existential distress, whereas psilocybin appears to engage broader existential and spiritual dimensions of well-being.
Broader Applicability: While this study focused on life-threatening illness, the existential dimensions of psilocybin's mechanism (meaning-making, death anxiety relief) suggest relevance for other conditions involving existential suffering — chronic illness, grief, life transitions, and identity challenges.
Compiled by Psychedelic Institute Australia. For PIA training staff and Essential Skills Program participants.
This summary covers the evidence base for psilocybin- and MDMA-assisted therapy — but evidence alone doesn't make someone qualified to deliver it safely. Our training and accreditation guide explains what "accredited" does and doesn't mean for psychedelic therapy training in Australia, and our guide to becoming a psychedelic therapist walks through who's eligible and what the training pathway actually involves.
Begin Your Journey
Our clinician-led training programs prepare you to work competently with psilocybin and MDMA-assisted therapy.